

## DAFTAR PUSTAKA

1. World Health Organization. Dementia [Internet]. WHO Newsroom. 2021 [cited 2022 Jan 17]. Available from: <https://www.who.int/news-room/fact-sheets/detail/dementia>
2. World Health Organization. Key Messages the Prevalence of Dementia Worldwide. World Heal Organ [Internet]. 2018;3–6. Available from: [http://www.who.int/mental\\_health/neurology/dementia/en/](http://www.who.int/mental_health/neurology/dementia/en/)-Diakses Februari 2022
3. Anstey KJ, Peters R. Dementia, Risk, Risk Reduction, and Translation into Practice: An International Research Network for Dementia Prevention (IRNDP) Special Issue. *J Alzheimer's Dis.* 2019;70(s1):S1–3.
4. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. *JAMA - J Am Med Assoc.* 2019;322(16):1589–99.
5. Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. *Mol Neurodegener.* 2019;14(1):1–18.
6. World Health Organization. WHO reveals leading causes of death and disability worldwide: 2000-2019 [Internet]. WHO News. 2020 [cited 2022 Jan 18]. Available from: <https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019>
7. Alzheimer's Indonesia. Statistik tentang Demensia [Internet]. <https://Alzi.or.Id/>. 2019 [cited 2022 Jan 30].
8. Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference? *Neurol Genet.* 2020;6(5):1–9.
9. Van Giau V, Bagyinszky E, Youn YC, An SSA, Kim SY. APP, PSEN1, and PSEN2 mutations in asian patients with early-onset alzheimer disease. *Int J Mol Sci.* 2019;20(19).
10. Rabinovici BGD. Late-onset Alzheimer Disease. 2019;(February):14–33.
11. Tiwari S, Venkata A, Kaushik A, Adriana Y, Nair M. Alzheimer ' s Disease Diagnostics And Therapeutics Market. *Int J Nanomedicine .* 2019;Jul 2019(14):5541–54.
12. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: Structure, biology and structure-based therapeutic development. *Acta Pharmacol Sin* [Internet]. 2017;38(9):1205–35.
13. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Mol*

Neurodegener. 2020;15(1):1–37.

14. Picón-Pagès P, Gutiérrez DA, Barranco-Almohalla A, Crepin G, Tajés M, Ill-Raga G, et al. Amyloid Beta-Peptide Increases BACE1 Translation through the Phosphorylation of the Eukaryotic Initiation Factor-2  $\alpha$ . *Oxid Med Cell Longev*. 2020;2020.
15. Association A. 2018 Alzheimer's disease facts and figures. *Alzheimer's Dement [Internet]*. 2018;14(3):367–429.
16. Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: An overview. *Int J Mol Sci*. 2021;22(4):1–21.
17. Noronha NDC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et al. Correction to: Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies (*Stem Cell Research and Therapy* (2019) 10 (131)). *Stem Cell Res Ther*. 2019;10(1):1–21.
18. Marino L, Castaldi MA, Rosamilio R, Ragni E, Vitolo R, Fulgione C, et al. Mesenchymal stem cells from the Wharton's jelly of the human umbilical cord: Biological properties and therapeutic potential. *Int J Stem Cells*. 2019;12(2):218–26.
19. Yang H, Xie ZH, Wei LF, Yang HN, Yang SN, Zhu ZY, et al. Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an A $\beta$ PP/PS1 transgenic mouse model. *Stem Cell Res Ther [Internet]*. 2013;4(4):1.
20. Millán-Rivero JE, Nadal-Nicolás FM, García-Bernal D, Sobrado-Calvo P, Blanquer M, Moraleda JM, et al. Human Wharton's jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors. *Sci Rep*. 2018;8(1):1–14.
21. Fernando KKM, Wijayasinghe YS. Sirtuins as Potential Therapeutic Targets for Mitigating Neuroinflammation Associated With Alzheimer's Disease. *Front Cell Neurosci*. 2021;15(September):1–15.
22. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 Suppresses  $\beta$ -Amyloid Production by Activating the  $\alpha$ -Secretase Gene ADAM10. *Cell [Internet]*. 2010;142(2):320–32.
23. Min XS, Sohn PD, Li Y, Devidze N, Johnson JR, Krogan XJ, et al. SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. 2018;38(15):3680–8.
24. Chuang Y, Van I, Zhao Y, Xu Y. Icaritin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting A $\beta$  cascade pathogenesis. *J Chem Neuroanat [Internet]*. 2021;117(35):102014.
25. Holmes C, Amin J. Dementia. *Med (United Kingdom)*. 2020;48(11):742–5.

26. Vinicius M, De Mello C, Vieira L, Cruz de Souza L, Gomes K, Carvalho M. Alzheimer's disease: risk factors and potentially protective measures. *J Biomed Sci* [Internet]. 2019;26(33):1–11.
27. Carmona S, Hardy J, Guerreiro R. The genetic landscape of Alzheimer disease [Internet]. 1st ed. Vol. 148, *Handbook of Clinical Neurology*. Elsevier B.V.; 2018. 395–408 p.
28. Haque RU, Levey AI. Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities. *Proc Natl Acad Sci U S A*. 2019;116(52):26224–9.
29. International AD, University M. World Alzheimer Report 2021. 2021; Available from: [https://www.alzint.org/resource/world-alzheimer-report-2021-Diakses Maret 2022](https://www.alzint.org/resource/world-alzheimer-report-2021-Diakses%20Maret%202022)
30. International AD. Dementia Statistics. Dement facts Fig [Internet]. [www.alzint.org/about/dementia-facts-figures/dementia-statistics/](http://www.alzint.org/about/dementia-facts-figures/dementia-statistics/)-Diakses Maret 2022
31. Nichols E, Szeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18(1):88–106.
32. Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer's disease. *Biomed Res Int*. 2019;2019.
33. Hara Y, McKeehan N, Fillit HM. Translating the biology of aging into novel therapeutics for Alzheimer disease. *Neurology*. 2019;92(2):84–93.
34. Menghani YR, Bhattad DM, Chandak KK, Taksande JR, Umekar MJ. A Review: Pharmacological and herbal remedies in The Management of Neurodegenerative disorder (Alzheimer's). *Int J Pharmacogn Life Sci*. 2021;2(1):18–27.
35. Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, et al. New Insights Into the Pathogenesis of Alzheimer's Disease. *Front Neurol*. 2020;10(January):1–12.
36. Ittner A, Ittner LM. Dendritic Tau in Alzheimer's Disease. *Neuron* [Internet]. 2018;99(1):13–27.
37. Simpson DSA, Oliver PL. Ros generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease. *Antioxidants*. 2020;9(8):1–27.
38. Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: Recent advances. *Mol Neurodegener*. 2020;15(1):1–22.

39. Swerdlow RH, Koppel S, Weidling I, Hayley C, Ji Y, Wilkins HM. Mitochondria, Cybrids, Aging, and Alzheimer's Disease. *Prog Mol Biol Transl Sci.* 2017;146:259–302.
40. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain.* 2018;141(7):1917–33.
41. Zvěřová M. Clinical aspects of Alzheimer's disease. *Clin Biochem.* 2019;72(February):3–6.
42. Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JCL. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. *Australas Psychiatry.* 2018;26(4):347–57.
43. Perhimpunan Dokter Spesialis Saraf Indonesia. Panduan Praktik Klinis Neurologi. *Perdossi.* 2016;154–6.
44. Musiał-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. *Cell Transplant.* 2019;28(7):801–12.
45. Kalimuthu S, Zhu L, Oh JM, Gangadaran P, Lee HW, Baek SH, et al. Migration of mesenchymal stem cells to tumor xenograft models and in vitro drug delivery by doxorubicin. *Int J Med Sci.* 2018;15(10):1051–61.
46. Prodromos CC, Joyce BT. Relative Strengths of Anterior Cruciate Ligament Autografts and Allografts [Internet]. Second Edi. *The Anterior Cruciate Ligament: Reconstruction and Basic Science: Second Edition.* Elsevier; 2018. 71-73.e1 p. A
47. Tahmasebi Birgani Z, Malhotra A, Yang L, Harink B, Habibovic P. Calcium phosphate ceramics with inorganic additives. *Compr Biomater II.* 2017;1(February 2016):406–27.
48. Jacobsen G, Easter D. Allograft vs Xenograft for Practical Consideration for Biologic Scaffolds. *UC San Diego Contin Med Educ [Internet].* 2009;4–7.
49. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. *Int Immunol.* 2017;29(2):49–58.
50. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. *Mol Ther.* 2004;10(6):1032–42.
51. In HI. Neural Stem Cell Transplantation into a Mouse Model of Stroke. In: *Chimera Research Methods in Molecular Biology.* Humana, New York; 2019. p. 153–63.
52. Li CL, Leng Y, Zhao B, Gao C, Du FF, Jin N, et al. Human iPSC-MSC-Derived Xenografts Modulate Immune Responses by Inhibiting the

Cleavage of Caspases. *Stem Cells*. 2017;35(7):1719–32.

53. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. *Blood*. 2005;106(2):756–63.
54. Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. *J Mol Cell Cardiol*. 2008;44(6):1072–84.
55. Kurtz A. Mesenchymal stem cell delivery routes and fate. *Int J Stem Cells*. 2008;1(1):1–7.
56. Zhang G, Li Y, Reuss JL, Liu N, Wu C, Li J, et al. Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke. *Stem Cells Transl Med*. 2019;8(10):999–1007.
57. Baumgartner J, Dash PK, Ph D, Jr CSC. Intravenous Mesenchymal Stem Cell Therapy for Traumatic Brain Injury. *J Neurosurg*. 2009;110(6):1189–97.
58. Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? *Pharm Res*. 2020;37(1).
59. Sadeghi S, Mosaffa N, Hashemi SM, Mehdi Naghizadeh M, Ghazanfari T. The immunomodulatory effects of mesenchymal stem cells on long term pulmonary complications in an animal model exposed to a sulfur mustard analog. *Int Immunopharmacol*. 2020;80(August).
60. Durk MR, Deshmukh G, Valle N, Ding X, Liederer BM, Liu X. Use of subcutaneous and intraperitoneal administration methods to facilitate cassette dosing in microdialysis studies in rats. *Drug Metab Dispos*. 2018;46(7):964–9.
61. Marzban M, Mousavizadeh K, Bakhshayesh M, Vousooghi N, Vakilzadeh G, Torkaman-Boutorabi A. Effect of multiple intraperitoneal injections of human bone marrow mesenchymal stem cells on cuprizone model of multiple sclerosis. *Iran Biomed J*. 2015;22(5):312–21.
62. Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? *Pharm Res*. 2020;37(1):1–30.
63. Kim J, Lee Y, Lee S, Kim K, Song M, Lee J. Mesenchymal Stem Cell Therapy and Alzheimer's Disease: Current Status and Future Perspectives. *J Alzheimer's Dis*. 2020;77(1):1–14.
64. Kim DH, Lim H, Lee D, Choi SJ, Oh W, Yang YS, et al. Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells

rescues neurons from synaptic dysfunction in Alzheimer's disease model. *Sci Rep*. 2018;8(1):1–13.

65. Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. 2018;1–9.
66. Doshmanziari M, Shirian S, Kouchakian M-R, Moniri SF, Jangnoo S, Mohammadi N, et al. Mesenchymal stem cells act as stimulators of neurogenesis and synaptic function in a rat model of Alzheimer's disease. *Heliyon* . 2021;7(9):e07996.
67. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. *Stem Cells Int*. 2016;2016.
68. Stefańska K, Ożegowska K, Hutchings G, Popis M, Moncrieff L, Dompe C, et al. Human Wharton's Jelly—cellular specificity, stemness potency, animal models, and current application in human clinical trials. *J Clin Med*. 2020;9(4).
69. Davies JE, Walker JT, Keating A. Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. *Stem Cells Transl Med*. 2017;6(7):1620–30.
70. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–7.
71. Campard D, Lysy PA, Najimi M, Sokal EM. Native Umbilical Cord Matrix Stem Cells Express Hepatic Markers and Differentiate Into Hepatocyte-like Cells. *Gastroenterology*. 2008;134(3):833–48.
72. Hashemitabar M, Allahbakhshi E, Tabande MR, Orazizadeh M, Dehbashi FN, Azandeh S, et al. Isolation and Characterization of Human Umbilical Cord Mesenchymal Stem Cells and Their Differentiation into Pdx-1<sup>+</sup> Cells. *J Biomed Sci Eng*. 2015;08(11):780–8.
73. Varaa N, Azandeh S, Khodabandeh Z, Gharravi AM. Wharton's Jelly mesenchymal stem cell: Various protocols for isolation and differentiation of hepatocyte-like cells; narrative review. *Iran J Med Sci*. 2019;44(6):437–48.
74. Puig-Pijuan T, De Godoy MA, Pinheiro Carvalho LR, Bodart-Santos V, Lindoso RS, Pimentel-Coelho PM, et al. Human Wharton's jelly mesenchymal stem cells protect neural cells from oxidative stress through paracrine mechanisms. *Futur Sci OA*. 2020;6(9).
75. Park SE, Kim HS, Kwon SJ, Kim MJ, Choi SJ, Oh SY, et al. Exposure of Mesenchymal Stem Cells to an Alzheimer's Disease Environment Enhances

Therapeutic Effects. *Stem Cells Int.* 2021;2021.

76. Lee IH. Mechanisms and disease implications of sirtuin-mediated autophagic regulation. *Exp Mol Med* [Internet]. 2019;51(9). Available from: <http://dx.doi.org/10.1038/s12276-019-0302-7>
77. Stamatovic SM, Martinez-Revollar G, Hu A, Choi J, Keep RF, Andjelkovic A V. Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging. *Neurobiol Dis* [Internet]. 2019;126:105–16.
78. Alkan C, Coe P, Eichler E. Distribution Analysis of Deacetylase SIRT1 in Rodent and Human Nervous Systems. *Bone*. 2011;23(1):1–7.
79. Mehramiz M, Porter T, Laws SM, Rainey-Smith SR. Sleep, *Sirtuin 1* and Alzheimer's disease: A review. *Aging Brain*. 2022;2:100050.
80. Lalla R, Donmez G. The role of sirtuins in Alzheimer's disease. *Front Aging Neurosci*. 2013;5(APR):1–4.
81. Wang J, Fivecoat H, Ho L, Pan Y, Ling E, Pasinetti GM. The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. *Biochim Biophys Acta - Proteins Proteomics*. 2010;1804(8):1690–4.
82. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid- $\beta$  toxicity through inhibiting NF- $\kappa$ B signaling. *J Biol Chem*. 2005;280(48):40364–74.
83. Jęśko H, Wencel P, Strosznajder RP, Strosznajder JB. Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders. *Neurochem Res*. 2017;42(3):876–90.
84. Ng F, Wijaya L, Tang BL. SIRT1 in the brain—connections with aging-associated disorders and lifespan. *Front Cell Neurosci*. 2015;9(March):1–13.
85. Pan S, Wu Y, Pei L, Li S, Song L, Xia H, et al. BML-111 reduces neuroinflammation and cognitive impairment in mice with sepsis via the SIRT1/NF- $\kappa$ B signaling pathway. *Front Cell Neurosci*. 2018;12(August):1–16.
86. Velagapudi R, El-Bakoush A, Lepiarz I, Ogunrinade F, Olajide OA. AMPK and SIRT1 activation contribute to inhibition of neuroinflammation by thymoquinone in BV2 microglia. *Mol Cell Biochem*. 2017;435(1–2):149–62.
87. Benedikz E, Kloskowska E, Winblad B. The rat as an animal model of Alzheimer's disease. *J Cell Mol Med*. 2009;13(6):1034–42.
88. S. DC, A.C. C. Modeling Alzheimer's disease in transgenic rats. *Mol*

Neurodegener. 2013;8(1):37.

89. Kaushal A, Wani WY, Anand R, Gill KD. Spontaneous and induced nontransgenic animal models of AD: Modeling AD using combinatorial approach. *Am J Alzheimers Dis Other Demen.* 2013;28(4):318–26.
90. Chen X, Zhang M, Ahmed M, Surapaneni KM, Veeraraghavan VP, Arulselvan P. Neuroprotective effects of ononin against the aluminium chloride-induced Alzheimer's disease in rats. *Saudi J Biol Sci* 2021;28(8):4232–9.
91. Liaquat L, Sadir S, Batool Z, Tabassum S, Shahzad S, Afzal A, et al. Acute aluminum chloride toxicity revisited: Study on DNA damage and histopathological, biochemical and neurochemical alterations in rat brain. *Life Sci [Internet].* 2019;217(November 2018):202–11.
92. Kim H, Na DL, Lee NK, Kim AR, Lee S, Jang H. Intrathecal injection in a rat model: A potential route to deliver human wharton's jelly-derived mesenchymal stem cells into the brain. *Int J Mol Sci.* 2020;21(4):1–11.
93. WHO. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization. 2000;1–73.
94. Maftuchah. *Teknik Dasar Analisis Biologi Molekuler.* Yogyakarta: Deepublish; 2014.
95. Polito L, Biella G, Albani D. Sirtuin Modulation as Novel Neuroprotective Strategy for Alzheimer's Disease [Internet]. *Neuroprotection in Alzheimer's Disease.* Elsevier Inc.; 2017. 149–173 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-803690-7/00008-9>
96. Shaw K. linked to Alzheimer ' s disease [Internet]. *Neuroprotection in Alzheimer's Disease.* Elsevier Inc.; 2017. 187–188 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-803690-7/00012-0>
97. Yuan Y, Cruzat VF, Newshome P, Cheng J, Chen Y, Lu Y. Regulation of SIRT1 in aging: Roles in mitochondrial function and biogenesis. *Mech Ageing Dev [Internet].* 2016;155(1):10–21.
98. Kumar R, Chaterjee P, Sharma PK, Singh AK, Gupta A, Gill K, et al. Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer's Disease. *PLoS One.* 2013;8(4):4–9.
99. U K. Both Activation and Inhibition of SIRT1 May Act via Exosomal GSK3 alpha/beta in the in - vitro Amyloid - beta Toxicity Model. *Adv Clin Toxicol.* 2019;4(4):1–14.
100. Almeida-Porada G, Atala AJ, Porada CD. Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery. *Mol Ther - Methods Clin Dev .* 2020;16(March):204–24.



101. Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. *J Cell Mol Med*. 2009;13(8 B):2547–58.
102. Kot M, Baj-Krzyworzeka M, Szatanek R, Musiał-Wysocka A, Suda-Szczurek M, Majka M. The importance of hla assessment in “off-the-shelf” allogeneic mesenchymal stem cells based-therapies. *Int J Mol Sci*. 2019;20(22).
103. Y. L, F. L. Mesenchymal stem cells are injured by complement after their contact with serum. *Blood*. 2012;120(1701–1710):3436–43.
104. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. *Front Immunol*. 2012;3(SEP):1–8.
105. Yousefi F, Ebtekar M, Soleimani M, Soudi S, Hashemi SM. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). *Int Immunopharmacol*. 2013;17(3):608–16.
106. Ramalho BDS, De Almeida FM, Sales CM, De Lima S, Martinez AMB. Injection of bone marrow mesenchymal stem cells by intravenous or intraperitoneal routes is a viable alternative to spinal cord injury treatment in mice. *Neural Regen Res*. 2018;13(6):1046–53.
107. Park D, Yang YH, Bae DK, Lee SH, Yang G, Kyung J, et al. Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase. *Neurobiol Aging*. 2013;34(11):2639–46.
108. Wei Y, Xie Z, Bi J, Zhu Z. Anti-inflammatory effects of bone marrow mesenchymal stem cells on mice with alzheimer’s disease. *Exp Ther Med*. 2018;16(6):5015–20.
109. Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. *Cells*. 2019;8(5).
110. Chen YA, Lu CH, Ke CC, Liu RS. Mesenchymal stem cell-derived extracellular vesicle-based therapy for alzheimer’s disease: Progress and opportunity. *Membranes (Basel)*. 2021;11(10):1–19.
111. Guo M, Yin Z, Chen F, Lei P. Mesenchymal stem cell-derived exosome: A promising alternative in the therapy of Alzheimer’s disease. *Alzheimer’s Res Ther*. 2020;12(1):1–14.
112. Yarni DS. Pengaruh Pemberian Mesenchymal Stem Cell Wharton Jelly Terhadap Ekspresi Gen Calm1 dan Casp9 Tikus Alzheimer (thesis). Padang

: Andalas University; 2021. <http://scholar.unand.ac.id/id/eprint/77683> - Diakses Februari 2022.

113. Endrinaldi E, Darwin E, Zubir N, Revilla G. The effect of mesenchymal stem cell wharton's jelly on matrix metalloproteinase-1 and interleukin-4 levels in osteoarthritis rat model. *Open Access Maced J Med Sci.* 2019;7(4):529–35.

